Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical gel containing naproxen, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing naproxen are listed in tablet, capsule and suspension forms. No naproxen product of any kind is listed in gel form.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that compounding pharmacies prepare as topical gels and creams and as oral liquids and capsules by prescription.
Naproxen is a propionic acid NSAID. It blocks the cyclooxygenase enzymes COX-1 and COX-2, which lowers prostaglandin production and with it pain, inflammation and fever. It is long acting, with a half-life of 12 to 17 hours. Manufactured naproxen and naproxen sodium tablets, delayed-release tablets and oral suspension (Naprosyn, EC-Naprosyn, Anaprox DS and generics) are FDA-approved for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendonitis, bursitis, acute gout, pain and primary dysmenorrhea. Over-the-counter naproxen sodium (Aleve) is labeled for minor aches and fever. No topical naproxen is manufactured in the United States. A prescriber might order compounded naproxen as a topical gel or cream, as a liquid or capsule strength not manufactured, or combined with other topical pain ingredients. Compounded preparations are not FDA-approved and require a prescription.
Oral naproxen carries two FDA boxed warnings. NSAIDs raise the risk of heart attack and stroke, which can be fatal and can occur early in treatment; naproxen must not be used around coronary artery bypass surgery. NSAIDs also raise the risk of stomach and intestinal bleeding, ulcers and perforation, which can occur without warning, especially in older adults. Do not use naproxen if aspirin or another NSAID has given you asthma, hives or a severe skin reaction. Bleeding risk rises with blood thinners, aspirin, corticosteroids and SSRI or SNRI antidepressants, and naproxen can blunt low-dose aspirin's heart protection, blood pressure medicines and diuretics, and raise lithium, methotrexate, digoxin and cyclosporine levels. Taking an NSAID at about 20 weeks of pregnancy or later may harm the unborn baby, so between 20 and 30 weeks use it only at the lowest dose for the shortest time your prescriber sets, and do not use it at about 30 weeks or later. LactMed reports low milk levels but prefers other drugs for newborns. Seek care for black stools, vomiting blood, chest pain, one-sided weakness or rash with fever. If side effects bother you, talk to your prescriber or pharmacist.
Naproxen competitively inhibits COX-1 and COX-2, with slightly greater COX-1 selectivity. Oral bioavailability is about 95%, peak levels occur at 1 to 4 hours (sooner with the sodium salt), protein binding exceeds 99%, and the half-life is 12 to 17 hours with steady state in 4 to 5 days. Hepatic metabolism to 6-O-desmethylnaproxen and glucuronides precedes about 95% urinary excretion; metabolites may accumulate in renal failure. Milk concentration is about 1 percent of maternal peak plasma. Labeled indications (naproxen tablets, delayed-release tablets and suspension; Naprosyn, EC-Naprosyn, Anaprox DS): rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis in children two and older, tendonitis, bursitis, acute gout, pain and primary dysmenorrhea. StatPearls lists off-label use in acute migraine and migraine prevention. Prescribers have ordered compounded topical naproxen for localized musculoskeletal pain; penetration modeling places naproxen among NSAIDs with measurable muscle deposition after topical application (Doktor et al., Int J Drug Deliv 2013). Dosing, strength and duration are per prescriber. Monitor blood pressure, renal function, CBC and GI symptoms with systemic exposure, plus INR with warfarin and lithium, methotrexate and digoxin levels when co-prescribed; the label carries a DRESS warning. Probenecid raises naproxen levels. Not a controlled substance.
Wash your hands. Apply the amount on your label to clean, dry skin and spread it in a thin layer. For a metered pump, your label states the number of presses. For a dosing syringe, push the plunger to the mark. Let the gel dry before covering with clothing. Wash your hands afterward and keep the site from touching other people until it has dried. Do not apply to broken skin unless told to.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Keep the container closed, away from heat and open flame if it contains alcohol, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)
